BCR and prostate cancer: Baas and colleagues retrospectively evaluated the predictive value for biochemical persistence (BCP) and early BCR of metastatic lymph node on PSMA PET/CT in 213 intermediate-risk and high-risk prostate cancer patients prior to radical treatment (RARP with ePLND).